Cypherpunk Technologies

Cypherpunk Technologies AAQS

The The AAQS of Cypherpunk Technologies (CYPH) as of Oct 16, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

Cypherpunk Technologies has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Cypherpunk Technologies in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Cypherpunk Technologies AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
4.00 USD
Jan 1, 2018
4.00 USD
Jan 1, 2019
4.00 USD
Jan 1, 2020
4.00 USD
Jan 1, 2021
4.00 USD
Jan 1, 2022
4.00 USD
Jan 1, 2023
4.00 USD
Jan 1, 2024
4.00 USD
The Cypherpunk Technologies AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cypherpunk Technologies Stock analysis

What does Cypherpunk Technologies do? Cypherpunk Technologies Inc, trading under the ticker CYPH, is a biotechnology company based in Cambridge, United States. The company has a small workforce of six employees. It went public with an IPO on January 24, 2017. The company's website is https://www.leaptx.com/. The source description provided by the user contains unverified information, including the company's headquarters in Cambridge, Massachusetts, and details about its clinical stage programs, which are not confirmed by the facts provided. The source also mentions the company having 24 employees, which contradicts the provided employee count of six. Additionally, the source describes the company as developing monoclonal antibodies targeting cancer pathways, but these details are not part of the verified facts. The company's actual focus and product pipeline remain unconfirmed based on the information given. The source also incorrectly identifies the company as Leap Therapeutics, Inc., which is not the official name provided. The website provided, https://www.leaptx.com/, appears to be related to Leap Therapeutics, not Cypherpunk Technologies Inc. Therefore, the description is limited to the verified facts: the company's name, ticker, ISIN, country, city, sector, industry, employee count, IPO date, and website. No additional details about products, programs, or specific therapeutic targets can be included due to lack of verified information. Cypherpunk Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cypherpunk Technologies stock

The AAQS of Cypherpunk Technologies is 4 in 2024.

On Eulerpool you can find the complete historical development of The AAQS Cypherpunk Technologies since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Cypherpunk Technologies

All Key Metrics — Cypherpunk Technologies